4.7 Article

DEAR1 Is a Chromosome 1p35 Tumor Suppressor and Master Regulator of TGF-β-Driven Epithelial-Mesenchymal Transition

Journal

CANCER DISCOVERY
Volume 3, Issue 10, Pages 1172-1189

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-12-0499

Keywords

-

Categories

Funding

  1. NCI Early Detection Research Network grant [5U01CA111302-08]
  2. Department of Defense [BC111524]
  3. Metastasis Research Center
  4. University of Texas MD Anderson Cancer Center
  5. Rosalie B. Hite Fellowship
  6. American Legion Auxiliary scholarship
  7. PEO (Philanthrophic Education Organization) Scholars award

Ask authors/readers for more resources

Deletion of chromosome 1p35 is a common event in epithelial malignancies. We report that DEAR1 (annotated as TRIM62) is a chromosome 1p35 tumor suppressor that undergoes mutation, copy number variation, and loss of expression in human tumors. Targeted disruption in the mouse recapitulates this human tumor spectrum, with both Dear1(-/-) and Dear1(+/-) mice developing primarily epithelial adenocarcinomas and lymphoma with evidence of metastasis in a subset of mice. DEAR1 loss of function in the presence of TGF-beta results in failure of acinar morphogenesis, upregulation of epithelial-mesenchymal transition (EMT) markers, anoikis resistance, migration, and invasion. Furthermore, DEAR1 blocks TGF-beta-SMAD3 signaling, resulting in decreased nuclear phosphorylated SMAD3 by binding to and promoting the ubiquitination of SMAD3, the major effector of TGF-beta- induced EMT. Moreover, DEAR1 loss increases levels of SMAD3 downstream effectors SNAIL1 and SNAIL2, with genetic alteration of DEAR1/SNAIL2 serving as prognostic markers of overall poor survival in a cohort of 889 cases of invasive breast cancer. SIGNIFICANCE: Cumulative results provide compelling evidence that DEAR1 is a critical tumor suppressor involved in multiple human cancers and provide a novel paradigm for regulation of TGF-beta- induced EMT through DEAR1's regulation of SMAD3 protein levels. DEAR1 loss of function has important therapeutic implications for targeted therapies aimed at the TGF-beta-SMAD3 pathway. (c) 2013 AACR.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available